内体
突触融合蛋白
高尔基体
内质网
细胞生物学
突触融合蛋白3
逆转体
转运蛋白
志贺毒素
伴侣(临床)
轴浆运输
化学
生物
膜蛋白
生物化学
基因
细胞内
膜
大肠杆菌
医学
病理
作者
Alison Forrester,Stefan J. Rathjen,María García-Castillo,Collin Bachert,Audrey Couhert,Livia Tepshi,Sylvain Pichard,Jennifer Martinez,Mathilde Munier,Raphaël Sierocki,Henri‐François Renard,César Augusto Valades-Cruz,Florent Dingli,Damarys Loew,Christophe Lamaze,Jean‐Christophe Cintrat,Adam D. Linstedt,Daniel Gillet,Julien Barbier,Ludger Johannes
标识
DOI:10.1038/s41589-020-0474-4
摘要
The retrograde transport inhibitor Retro-2 has a protective effect on cells and in mice against Shiga-like toxins and ricin. Retro-2 causes toxin accumulation in early endosomes and relocalization of the Golgi SNARE protein syntaxin-5 to the endoplasmic reticulum. The molecular mechanisms by which this is achieved remain unknown. Here, we show that Retro-2 targets the endoplasmic reticulum exit site component Sec16A, affecting anterograde transport of syntaxin-5 from the endoplasmic reticulum to the Golgi. The formation of canonical SNARE complexes involving syntaxin-5 is not affected in Retro-2-treated cells. By contrast, the interaction of syntaxin-5 with a newly discovered binding partner, the retrograde trafficking chaperone GPP130, is abolished, and we show that GPP130 must indeed bind to syntaxin-5 to drive Shiga toxin transport from the endosomes to the Golgi. We therefore identify Sec16A as a druggable target and provide evidence for a non-SNARE function for syntaxin-5 in interaction with GPP130. The ER exit site component Sec16A was identified as the target of Retro-2, a small-molecule inhibitor of protein toxins and pathogens. Retro-2 treatment alters retrograde early/maturing endosomes-to-Golgi trafficking of Shiga toxin.
科研通智能强力驱动
Strongly Powered by AbleSci AI